HOME > ARCHIVE
ARCHIVE
- New Orphan Drugs, Medical Device Announced
May 28, 2001
- Rituximab Recommended for Approval: CDFS
May 21, 2001
- Korosho Issues Notifications of Revision of Specifications and Test Method Guidelines
May 21, 2001
- Average Household's Healthcare Spending Down in FY2000
May 21, 2001
- Preparations in Progress for Advent of CTD in July
May 21, 2001
- Japanese Global Strategy Update (2)
May 21, 2001
- Keidanren, Nikkeiren to Propose Independent Health Insurance for Elderly
May 21, 2001
- Snow Brand Milk to Transfer Its Pharma Business to Daiichi
May 21, 2001
- Over 40% of Doctors Recognize Usefulness of Large-scale Trials: Survey
May 21, 2001
- Fujisawa to Transfer Animal Health Business to Schering-Plough
May 21, 2001
- Increasing Number of Firms Try to Obtain Information on Competitors Based on Information Access Law
May 21, 2001
- Shionogi USA Established
May 21, 2001
- REGULATORY NEWS IN BRIEF
May 21, 2001
- Santen Ties Up with PDI for Levofloxacin
May 21, 2001
- JMA to Start Monitoring Medical Facilities' Business Performance
May 21, 2001
- SSP, Nihon Tenganyaku to Jointly Research Antifungal Eye Drop
May 21, 2001
- \240,000 Necessary per Month forNursing Care: Survey Respondents
May 21, 2001
- Kissei Completes Therapeutic Nutritive Food Business Center
May 21, 2001
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
May 21, 2001
- Ethical Drugs Achieve 2.5% Growth in FY2000
May 21, 2001
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
